NeoGenomics (NEO) 10-Q 10 May 16 2016 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2016	Apr. 20, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Trading Symbol	NEO
Entity Registrant Name	NEOGENOMICS INC
Entity Central Index Key	1,077,183
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		77,117,678

CONSOLIDATED BALANCE SHEETS (Un

CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Current assets
Cash and cash equivalents	$ 19,256	$ 23,420
Accounts receivable (net of allowance for doubtful accounts of $7,343 and $4,759, respectively)	50,088	48,943
Inventories	5,334	5,108
Other current assets	6,525	4,889
Total current assets	81,203	82,360
Property and equipment (net of accumulated depreciation of $30,135 and $26,534, respectively)	33,559	34,577
Intangible assets, net	85,774	87,800
Goodwill	146,179	146,421
Other assets	129	129
Total assets	346,844	351,287
Current liabilities
Accounts payable	15,288	12,464
Accrued compensation	9,185	6,217
Accrued expenses and other liabilities	4,980	7,374
Revolving credit facility, net		8,869
Short-term portion of capital leases	4,267	4,534
Short-term portion of loans	596	600
Total current liabilities	34,316	40,058
Long-term liabilities
Long-term portion of capital leases	4,124	5,040
Long-term portion of loans, net	52,316	52,336
Deferred income tax liability, net	15,916	15,741
Total long-term liabilities	72,356	73,117
Total liabilities	$ 106,672	$ 113,175
Commitments and contingencies - see Note I
Stockholders' equity
Common stock, $.001 par value, (250,000,000 shares authorized; 77,033,608 and 75,820,307 shares issued and outstanding, respectively)	$ 77	$ 76
Additional paid-in capital	233,401	231,375
Accumulated deficit	(27,475)	(21,941)
Total stockholders’ equity	206,003	209,510
Total liabilities, redeemable convertible preferred stock and stockholders' equity	346,844	351,287
Series A Redeemable Convertible Preferred Stock [Member]
Redeemable convertible preferred stock:
Series A Redeemable Convertible Preferred Stock, $0.01 par value, (50,000,000 shares authorized; and 14,666,667 shares issued and outstanding, respectively)	$ 34,169	$ 28,602

CONSOLIDATED BALANCE SHEETS (U3

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Accounts receivable, allowance for doubtful accounts	$ 7,343	$ 4,759
Property and equipment, accumulated depreciation	$ 30,135	$ 26,534
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	77,033,608	75,820,307
Common stock, shares outstanding	77,033,608	75,820,307
Series A Redeemable Convertible Preferred Stock [Member]
Redeemable Convertible Preferred Stock, par value	$ 0.01	$ 0.01
Redeemable Convertible Preferred Stock, shares authorized	50,000,000	50,000,000
Redeemable Convertible Preferred Stock, shares issued	14,666,667	14,666,667
Redeemable Convertible Preferred Stock, shares outstanding	14,666,667	14,666,667

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
NET REVENUE
Clinical testing revenue	$ 54,622	$ 22,839
BioPharma & research revenue	5,082	187
Total Revenue, net	59,704	23,026
COST OF REVENUE	32,531	13,482
GROSS MARGIN	27,173	9,544
Operating expenses:
General and administrative	18,005	6,522
Research and development	1,446	669
Sales and marketing	5,800	2,914
Total Operating Expenses	25,251	10,105
INCOME (LOSS) FROM OPERATIONS	1,922	(561)
Interest expense, net	1,593	195
Income (loss) before taxes	329	(756)
Income tax expense	174	5
NET INCOME (LOSS)	155	(761)
Deemed dividends on preferred stock	1,840
Amortization of preferred stock beneficial conversion feature	3,727
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$ (5,412)	$ (761)
NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS
Basic	$ (0.07)	$ (0.01)
Diluted	$ (0.07)	$ (0.01)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic	76,068	60,277
Diluted	76,068	60,277

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES
Net income (loss)	$ 155	$ (761)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities, net of business acquisition:
Depreciation	3,585	1,586
Amortization of intangibles	2,026	93
Amortization of debt issue costs	182
Stock based compensation – options, restricted stock and warrants	703	401
Provision for bad debts	2,663	602
Changes in assets and liabilities, net of business acquisition:
(Increase) in accounts receivable, net of write-offs	(3,809)	(1,610)
(Increase) decrease in inventories	(225)	21
Decrease (increase) in prepaid expenses	(401)	(42)
Decrease in other current assets		1
(Decrease) in accounts payable and other liabilities	2,180	(1,078)
Net cash provided by (used in) operating activities	7,059	(787)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment	(1,001)	(842)
Net cash used in investing activities	(1,001)	(842)
CASH FLOWS FROM FINANCING ACTIVITIES
Repayment of revolving credit facility	(10,044)
Repayment of capital lease obligations/loans	(1,379)	(921)
Issuance of common stock for the exercise of options, warrants and ESPP shares, net of transaction expenses	1,201	109
Net cash used in financing activities	(10,222)	(812)
Net change in cash and cash equivalents	(4,164)	(2,441)
Cash and cash equivalent, beginning of period	23,420	33,689
Cash and cash equivalents, end of period	19,256	31,248
Supplemental disclosure of cash flow information:
Interest paid	1,416	212
Income taxes paid	207	5
Supplemental disclosure of non-cash investing and financing information:
Equipment acquired under capital lease/loan obligations	$ 173	$ 2,525

Nature of Business and Basis of

Nature of Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Nature of Business and Basis of Presentation	Note A – Nature of Business and Basis of Presentation NeoGenomics, Inc., a Nevada corporation (the “Parent” or the “Parent Company”), and its subsidiaries, NeoGenomics Laboratories, Inc., a Florida corporation (“NEO” or, “NeoGenomics Laboratories”), Path Labs LLC., a Delaware Limited Liability Corporation (“PathLogic”) and Clarient Inc., a Delaware Corporation, and its wholly-owned subsidiary Clarient Diagnostic Services, Inc. (together, “Clarient”), (collectively referred to as “we”, “us”, “our”, “NeoGenomics”, or the “Company”), operates as a certified “high complexity” clinical laboratory in accordance with the federal government’s Clinical Laboratory Improvement Act, as amended (“CLIA”), and is dedicated to the delivery of clinical diagnostic services to pathologists, oncologists, urologists, hospitals, and other laboratories throughout the United States. The accompanying interim consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information. These accompanying interim consolidated financial statements include the accounts of the Parent and its subsidiaries. All intercompany transactions and balances have been eliminated in the accompanying interim consolidated financial statements. Certain information and footnote disclosures normally included in the Company’s annual audited consolidated financial statements and accompanying notes have been condensed or omitted in these accompanying interim consolidated financial statements. Accordingly, the accompanying interim consolidated financial statements included herein should be read in conjunction with the audited consolidated financial statements and accompanying notes included in the Company’s annual report on Form 10-K for the year ended December 31, 2015, filed with the Securities and Exchange Commission (the “SEC”) on March 15, 2016 and as amended and filed with the SEC on April 18, 2016. The results of operations presented in this quarterly report on Form 10-Q are not necessarily indicative of the results of operations that may be expected for any future periods. In the opinion of management, these unaudited consolidated financial statements include all adjustments and accruals, consisting only of normal recurring adjustments that are necessary for a fair statement of the results of all interim periods reported herein. We have one reportable operating segment that delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers and represents 100% of the Company’s consolidated assets, net revenues and net income for each of the quarters ended March 31, 2016 and 2015. Also, at March 31, 2106, all of our services were provided within the United States and all of our assets were located in the United States. Reclassification of Prior Year Presentation Certain prior period amounts have been reclassified for consistency with the current period presentation. For the period ended March 31, 2016, the Company retrospectively adopted ASU 2015-17 and thus revised the classification of deferred tax assets on the Consolidated Balance Sheets. The deferred tax assets that were presented as of December 31, 2015 have offset the deferred tax liabilities and been presented as a long term liability under the description deferred tax liabilities, net. The Company also revised the classification on the Consolidated Statement of Operations by separating other income from interest expense. These changes in classification have no net effect on the previously reported cash flows in the Consolidated Statements of Cash Flows, Consolidated Balance Sheets or Statements of Operations for any period.

Recently Issued Accounting Guid

Recently Issued Accounting Guidance	3 Months Ended
	Mar. 31, 2016
Accounting Changes And Error Corrections [Abstract]
Recently Issued Accounting Guidance	Note B — Recently Issued Accounting Guidance Effective January 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-17, Income Taxes. The standard update was issued to simplify the presentation of deferred income taxes and required deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. ASU 2015-17 is effective for fiscal years and interim periods within those fiscal years, beginning after December 31, 2016. Earlier application is permitted as of the beginning of an interim or annual period. The Company has early adopted this ASU and applied the amendments retrospectively to all deferred tax liabilities and assets presented. The effect of the adoption on the Consolidated Balance Sheet as of March 31, 2016 and December 31, 2015, was the offset of long term deferred tax liabilities by current deferred tax assets of $16,668,000. Effective September 2015, the FASB issued ASU 2015-16, Business Combinations. The standard update was issued to simplify the accounting for measurement period adjustments. The update requires that adjustments to provisional amounts identified during the measurement period be recognized in the period determined. The effect of these adjustments on current earnings that would have been related to previously reported earnings is required to be disclosed. ASU 2015-16 is effective for fiscal years and interim periods within those fiscal years, beginning after December 31, 2015. The update should be applied prospectively to adjustments that occur after the effective date of this update. The Company has adopted this ASU 2015-16 and it did not have a material effect on Company’s earnings for the period ended March 31, 2016.

Acquisitions

Acquisitions	3 Months Ended
	Mar. 31, 2016
Business Combinations [Abstract]
Acquisitions	Note C — Acquisitions Clarient On December 30, 2015 (“the acquisition date”), the Company acquired from GE Medical Holding AB (“GE Medical”), a subsidiary of General Electric Company (“GE”), all of the issued and outstanding shares of common stock of Clarient, Inc., (“Clarient”) a wholly owned subsidiary of GE Medical, for a purchase price consisting of (i) cash consideration of approximately $73.8 million, which includes an approximately $6.7 million estimated working capital adjustment and adjustments for estimated cash on hand and estimated indebtedness of Clarient on the Closing Date, (ii) 15,000,000 shares of NeoGenomics’ common stock, and (iii) 14,666,667 shares of NeoGenomics’ Series A Preferred Stock pursuant to the Stock Purchase Agreement. The cash consideration paid as part of the purchase price was funded through the following: · The Company paid approximately $10.7 million using cash on hand · Approximately $9.5 million, net of transaction costs was funded using a revolving credit facility · Approximately $53.6 million, net of transaction costs was funded using a term loan On December 21, 2015 shareholders approved and on December 28, 2015, NeoGenomics filed with the Secretary of State of the State of Nevada amendments to its Articles of Incorporation to increase the authorized number of shares of common stock from 100.0 million shares to 250.0 million shares and to increase the authorized number of shares of preferred stock from 10.0 million shares to 50.0 million shares in order to fund the common and preferred stock portion of the purchase price. The Company issued 15,000,000 shares of common stock as consideration for the acquisition of Clarient. The common stock includes restrictions imposed on the holder in the I Common Stock Valuation Amount Shares of common stock issued as consideration 15,000,000 Stock price per share on closing date $ 8.04 Value of common stock issued as consideration $ 120,600 Issue discount due to lack of marketability $ (18,090 ) Fair value of common stock at December 30, 2015 $ 102,510 The Company issued 14,666,667 shares of Series A Preferred Stock as consideration for the acquisition of Clarient. The rights of the Series A Preferred Stock are described in Note F. We estimated the fair value of the Series A Preferred Stock consideration using significant inputs not observable in the market and thus represents a Level 3 measurement as defined in ASC 820. The fair value of the Series A Preferred Stock at the acquisition date was $73.2 million or $4.99 per share. This fair value was further reduced by the intrinsic value assigned to the beneficial conversion feature to arrive at a carrying amount of $28.6 million. On a fully diluted basis, assuming full conversion of the Series A Preferred Stock, GE Medical would own approximately 32% of NeoGenomics. In addition, p ursuant to the I The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the acquisition date of December 30, 2015. The Company is in the process obtaining input from third-party valuations of its tangible and intangible assets and other information necessary to measure the remaining assets acquired and liabilities assumed; thus, the provisional measurements of current assets, property and equipment, intangible assets, goodwill, current liabilities, net deferred tax liabilities and long-term liabilities are subject to change. The preliminary acquisition fair values below are presented as of December 30, 2015 (in thousands): December 30, 2015 (As Initially Reported) Measurement Period Adjustments December 30, 2015 (As Adjusted) Current assets, including cash and cash equivalents of $890 $ 31,978 $ - $ 31,978 Property and equipment 19,241 - 19,241 Identifiable intangible assets – customer relationships 84,000 - 84,000 Goodwill 143,493 (242 ) 143,251 Total assets acquired 278,712 (242 ) 278,470 Current liabilities (12,631 ) 242 (12,389 ) Deferred tax liability (17,904 ) - (17,904 ) Long-term liabilities (103 ) - (103 ) Net assets acquired $ 248,074 $ - $ 248,074 Of the $84.0 million of acquired intangible assets, $81.0 million was provisionally assigned to customer relationships which are being amortized over fifteen years and $3.0 million was provisionally assigned to trade names which are being amortized over two years. For the periods ending March 31, 2016 and December 31, 2015, we recorded approximately $1.9 million and $36,000 of amortization expense respectively. The amortization expense for the period ended December 31, 2015 represented two days of ownership of Clarient. Goodwill arising from the acquisition of Clarient includes revenue synergies as a result of our existing customers and Clarient’s customers having access to each other’s testing menus and capabilities and also from the new product lines which Clarient adds to the Company’s product portfolio. None of the goodwill is expected to be deductible for income tax purposes. The provisional fair value of accounts receivable acquired is approximately $27.6 million The Company recognized acquisition related transaction costs of approximately $4.7 million during the year ended December 31, 2015. These costs include due diligence, legal, consulting and other transaction related expenses associated with the acquisition of Clarient. These expenses were included in general and administrative expenses in our consolidated statements of operations for the year ended December 31, 2015. The Company also incurred debt issuance costs of $3.3 million which are recorded as reductions in the carrying amount of the related liabilities and are being amortized over the term of the loans. The following unaudited pro forma information (in thousands), have been provided for illustrative purposes and are not necessarily indicative of results that would have occurred had the Acquisition been in effect since January 1, 2014, nor are they necessarily indicative of future results. March 31 2015 Revenue $ 54,316 Net (loss) attributable to common stockholders (45,526 ) (Loss) per share $ (0.60 ) Basic 75,277 Diluted 75,277 The unaudited pro forma consolidated results during the quarter ended March 31, 2015 have been prepared by adjusting our historical results to include the Acquisition as if it occurred on January 1, 2014. These unaudited pro forma consolidated historical results were then adjusted for the following: · Remove transaction expenses from the year ended December 31, 2015 and record them in the year ended December 31, 2014 · Adjustments to reflect amortization and depreciation expense associated with the acquired assets, partially offset by the elimination of the amortization and depreciation expense associated with Clarient’s historical assets. · Removal of costs associated with MultiOmyx, assets not acquired in the transaction, and to record royalty fees due to GE for continued use of the MultiOmyx product through a licensing agreement. · Remove general and administrative expenses related to a Lab Services Agreement with the Saudi Arabian National Guard Health Affairs, as GE Medical has retained this agreement. · Record interest expense under the Credit Facilities and amortization of financing costs classified as interest expense. · Remove royalty costs associated with the use of the GE brand as NeoGenomics will discontinue the use of the GE brand. · Accrue for dividends on the Series A Preferred stock and to amortize a portion of the beneficial conversion feature As noted above, the unaudited pro forma results of operations do not purport to be indicative of the actual results that would have been achieved by the combined Company for the periods presented or that may be achieved by the combined Company in the future.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	3 Months Ended
	Mar. 31, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Note D — Goodwill and Intangible Assets The Company has recorded Goodwill of $146.2 million as of March 31, 2016. The changes in the carrying amount of goodwill for the three month period ended March 31, 2016 and for the year ended December 31, 2015 are as follows (in thousands): March 31, December 31, 2016 2015 Balance as of January 1 $ 146,421 $ 2,929 Goodwill acquired during the period - 143,492 Adjustment to preliminary value of goodwill (Note C) (242 ) - Balance at end of period $ 146,179 $ 146,421 Intangible assets as of March 31, 2016 and December 31, 2015 consisted of the following (in thousands): March 31, 2016 Amortization Period Cost Accumulated Amortization Net Trade Name 24 months $ 3,000 $ 383 $ 2,617 Customer Relationships 156 months 82,930 1,842 81,088 Support Vector Machine (SVM) technology 108 months 500 227 273 Laboratory developed test (LDT) technology 164 months 1,482 443 1,039 Flow Cytometry and Cytogenetics technology 202 months 1,000 243 757 Total $ 88,912 $ 3,138 $ 85,774 December 31, 2015 Amortization Period Cost Accumulated Amortization Net Trade Name 24 months $ 3,000 $ 8 $ 2,992 Customer Relationships 156 months 82,930 247 82,683 Support Vector Machine (SVM) technology 108 months 500 213 287 Laboratory developed test (LDT) technology 164 months 1,482 416 1,066 Flow Cytometry and Cytogenetics technology 202 months 1,000 228 772 Total $ 88,912 $ 1,112 $ 87,800 We recorded approximately $2.0 million and $93,000 in straight-line amortization expense of intangible assets in the three months ended March 31, 2016 and 2015, respectively. The Company recorded amortization expense from customer relationships and trade names as a general and administrative expense. We will continue to record the amortization of the Support Vector Machine (SVM) technology, the Laboratory developed tests (LDT) technology and the Flow Cytometry and Cytogenetics technology intangible assets as a research and development expense until the such time that we have products, services or cost savings directly attributable to these intangible assets that would require recordation in cost of goods sold. The estimated amortization expense related to amortizable intangible assets for each of the five succeeding fiscal years and thereafter as of March 31, 2016 is as follows (in thousands): Year Ending December 31, Remainder of 2016 $ 5,246 2017 7,264 2018 5,771 2019 5,771 2020 5,771 2021 5,726 Thereafter 50,225 Total $ 85,774

Debt

Debt	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Debt	Note E — Debt Term Loan On December 30, 2015, the Company entered into a Term Loan and Guaranty Agreement (the “Term Loan Facility”) for which AB Private Credit Investors LLC is to act as the administrative agent and collateral agent. The agreement provides for $55.0 million of borrowings. On March 31, 2016, the Company had current outstanding borrowings of $550,000 and long-term outstanding borrowings of $52.2 million, net of unamortized debt issuance costs of $2.2 million. The fair value of the Company’s Term loan is estimated by discounting the future cash flow using the Company’s current borrowing rates for similar types and maturities of debt, except for floating-rate notes for which the carrying amounts were considered a reasonable estimate of fair value. The interest rate for borrowings under the Term Loan Facility will be, at NeoGenomics Laboratories’ election, (i) (A) a base rate equal to the greatest of 4%, the prime rate, the federal funds rate plus 0.5% and the one month LIBOR rate plus 1%, plus (B) an initial applicable margin of 6% , or (ii) the (A) LIBOR rate for interest periods from one to twelve months, plus (B) an initial applicable margin of 7%, with a minimum LIBOR of 1.00%. Interest on borrowings under the facility will be reduced to Base Rate plus 5.5% or LIBOR plus 6.50% upon the later of (i) NeoGenomics’ achieving maximum total leverage of less than 2.0 to 1.0 and (ii) January 1, 2017. NeoGenomics and all of its present and future subsidiaries (other than NeoGenomics Laboratories) are guarantors under the Term Loan Facility. The Term Loan Facility contains the following financial covenants: (i) maintenance of a maximum total leverage ratio of 4.0 to 1.0 (stepping down over time to 3.25 to 1.0), and (ii) maintenance of a minimum consolidated fixed charge coverage ratio of 1.10 to 1.0 (stepping up over time to 1.25 to 1.0). These covenants are effective beginning with the quarter ending March 31, 2016. The Company was in compliance with all such covenants as of March 31, 2016. The Term Loan Facility also contains various affirmative and negative covenants, such as the delivery of financial statements, tax authority compliance, maintenance of property, limitations on additional debt, restriction of dividends and other standard clauses. The Term Loan Facility has a maturity of five years. In addition, the Term Loan Facility provides for annual amortization payments in an amount equal to 1.0% of the original principal amount of the term loan, paid in quarterly installments, and mandatory prepayments with (i) proceeds of certain assets sales and recovery events, (ii) proceeds of certain debt issuances, (iii) proceeds of certain extraordinary receipts, as defined, (iv) a portion of certain tax refunds and insurance proceeds, and (v) a portion of excess cash flow as defined. Auto Loans The company has auto loans with various financial institutions. The auto loan terms range from 36-60 months and carry interest rates from 0.0% to 5.2%. Maturities of Long-Term Debt Maturities of long-term debt at March 31, 2016 are summarized as follows (in thousands): Term Loan Auto Loans Total Long Term Debt Remainder of 2016 $ 413 $ 40 $ 453 2017 550 40 590 2018 550 18 568 2019 550 14 564 2020 52,937 4 52,941 $ 55,000 $ 116 $ 55,116 Less: Current portion of long-term debt (550 ) (46 ) (596 ) Less: Debt issuance costs, net (2,204 ) - (2,204 ) Long-term debt, net $ 52,246 $ 70 $ 52,316 Short-Term Debt - Revolving Credit Facility On December 30, 2015, the Company entered into a Credit Agreement (the “Revolving Credit Facility”) for which Wells Fargo Bank, N.A., is to act as the administrative agent. The Revolving Credit Facility provides for up to $25.0 million of revolving loans and a letter of credit subfacility for $1.0 million. Borrowings under the revolver and the letter of credit subfacility are limited to a borrowing base comprised of 85% of the expected net value of certain billed and unbilled accounts receivable less reserve amounts established by Wells Fargo Bank, N.A. The carrying amount of the Revolving Credit Facility approximates fair value due to the short maturity and their variable market rates of interest that change with current Prime and no change in counterparty credit risk and were classified as Level 2 of the fair value hierarchy. The interest rate for borrowings under the Revolving Credit Facility will be, at NeoGenomics Laboratories’ election, (i) (A) a base rate equal to the greatest of the prime rate, the federal funds rate plus 0.5% and the three month LIBOR rate plus 1%, plus (B) an applicable margin ranging from 2.0% to 2.5%, or (ii) the (A) LIBOR rate plus (B) an applicable margin ranging from 3.0% to 3.5%. NeoGenomics will also pay 0.25% per year on any unused portion of the revolver. NeoGenomics is a guarantor under the Revolving Credit Facility. All of NeoGenomics’ present and future subsidiaries (including NeoGenomics Laboratories) are borrowers under the Revolving Credit Facility. The Revolving Credit Facility contains the following financial covenants: (i) maintenance of a maximum total leverage ratio (funded indebtedness (including the outstanding amounts under the Credit Facilities), plus capitalized lease obligations, divided by EBITDA) of not more than 4.0 to 1.0 (stepping down over time to 3.25 to 1.0), (ii) maintenance of a minimum consolidated fixed charge coverage ratio (EBITDA less capital expenditures not financed with debt or certain equity), divided by the sum of cash interest expense, scheduled payments and mandatory prepayments of principal on indebtedness, taxes and restricted payments) of at least 1.1 to 1.0 (stepping up over time to 1.25 to 1.0) and (iii) maintenance of a minimum cash velocity equal to or greater than 80%. These covenants are effective beginning with the quarter ending March 31, 2016. The Company was in compliance with such all covenants as of March 31, 2016. The Revolving Credit Facility also contains various affirmative and negative covenants, such as the delivery of financial statements, tax authority compliance, maintenance of property, limitations on additional debt, restriction of dividends and other standard clauses. The Revolving Credit Facility has a maturity of five years, maturing on December 30, 2020. In addition, the Revolving Credit Facility provides for mandatory prepayment in the event that the borrowing base is less than the aggregate amount of the advances outstanding under the revolver and any letters of credit, which prepayment will be equal to the amount necessary to remedy the over-advance. At March 31, 2016, the Company had no outstanding borrowings under the Revolving Credit Facility, nor under the letter of credit subfacility. The related debt issuance costs of approximately $1.2 million have been reclassified into other current assets. There is approximately $25 million in available credit under the Revolving Credit Facility to be drawn upon as needed.

Class A Redeemable Convertible

Class A Redeemable Convertible Preferred Stock	3 Months Ended
	Mar. 31, 2016
Temporary Equity Disclosure [Abstract]
Class A Redeemable Convertible Preferred Stock	Note F — Class A Redeemable Convertible Preferred Stock On December 30, 2015, the Company issued 14,666,667 shares of its Series A Redeemable Convertible Preferred stock (“Series A Preferred Stock”) as part of the consideration for the acquisition of Clarient, see Note C. The Series A Preferred Stock has a face value of $7.50 per share for a total liquidation value of $110 million. The Company recorded the Series A Preferred Stock at a fair value of approximately $73.2 million or $4.99 per share on the date of issuance. The difference between the fair value of $73.2 million and the liquidation value of $110 million represents a discount of $36.8 million from the initial face value as a result of assessing the impact the rights and features (listed below) of the instrument and their effect on the value to the issuer and holder. Beneficial Conversion Feature The fair value of the common stock into which the Series A Preferred Stock was convertible at the date of issuance exceeded the allocated purchase price fair value of the Series A Preferred Stock by approximately $44.7 million on the date of issuance, resulting in a beneficial conversion feature. The Company will recognize the beneficial conversion feature as non-cash, deemed dividend to the holders of Series A Preferred Stock over the first three years the Series A Preferred Stock is outstanding, as the date the stock first becomes convertible is three years from the issue date. The amount recognized for the period ended March 31, 2016 was approximately $1.8 million. Classification The Company classified the convertible preferred stock as temporary equity on the consolidated balance sheets due to certain change in control events that are outside the Company’s control, including deemed liquidation events described in the Series A Certificate of Designation.

Revenue Recognition and Contrac

Revenue Recognition and Contractual Adjustments	3 Months Ended
	Mar. 31, 2016
Revenue Recognition [Abstract]
Revenue Recognition and Contractual Adjustments	Note G — Revenue Recognition and Contractual Adjustments The Company recognizes revenues when (a) the price is fixed or determinable, (b) persuasive evidence of an arrangement exists, (c) the service is performed and (d) collectability of the resulting receivable is reasonably assured. The Company’s specialized diagnostic services are performed based on a written test requisition form or electronic equivalent, and revenues are recognized once the diagnostic services have been performed, and the results have been delivered to the ordering physician. These diagnostic services are billed to various payers, including Medicare, commercial insurance companies, other directly billed healthcare institutions such as hospitals and clinics, and individuals. The Company reports revenues from contracted payers, including Medicare, certain insurance companies and certain healthcare institutions, based on the contractual rate, or in the case of Medicare, published fee schedules. The Company reports revenues from non-contracted payers, including certain insurance companies and individuals, based on the amount expected to be collected. The difference between the amount billed and the amount estimated to be collected from non-contracted payers is recorded as an allowance to arrive at the reported net revenues. The expected revenues from non-contracted payers are based on the historical collection experience of each payer or payer group, as appropriate. The Company records revenues from patient pay tests net of a large discount and as a result recognizes minimal revenue on those tests. The Company regularly reviews its historical collection experience for non-contracted payers and adjusts its expected revenues for current and subsequent periods accordingly. The table below shows the adjustments made to gross service revenues to arrive at net revenues (in thousands), the amount reported on our statements of operations. Three Months Ended March 31, 2016 2015 Gross service revenues $ 132,720 $ 53,631 Total contractual adjustments and discounts (73,016 ) (30,605 ) Net revenues $ 59,704 $ 23,026

Equity

Equity	3 Months Ended
	Mar. 31, 2016
Equity [Abstract]
Equity	Note H — Equity A summary of the stock option activity under the Company’s plans for the three months ended March 31, 2016 is as follows: Number of Weighted average shares exercise price Options outstanding at December 31, 2015 5,326,505 $ 3.07 Options granted 762,500 6.77 Less: Options exercised 1,218,292 0.92 Options canceled or expired 139,542 4.68 Options outstanding at March 31, 2016 4,731,171 3.42 Exercisable at March 31, 2016 1,753,494 $ 2.32 As of March 31, 2016, there was approximately $4.0 million of unrecognized share based compensation expense related to stock options that will be recognized over a weighted-average period of approximately 1.4 years. Stock based compensation expense recognized for stock options and restricted stock and included in the consolidated statements of operations was allocated as follows (in thousands): Three Months Ended March 31, 2016 2015 Research and development expense $ (9 ) $ 55 General and administrative expense 796 287 Total stock based compensation expense $ 787 $ 342 Stock based compensation recorded in research and development relates to unvested options and warrants granted to a non-employee. Common Stock Warrants A summary of the warrant activity for the three months ended March 31, 2016 is as follows: Number of Weighted average shares exercise price Warrants outstanding at December 31, 2015 650,000 $ 1.48 Warrants granted — — Less: Warrants exercised — — Warrants canceled or expired — — Warrants outstanding at March 31, 2016 650,000 1.48 Exercisable at March 31, 2016 530,000 $ 1.49 During the three months ended March 31, 2016 and 2015, we recorded $(84,000) and $59,000 of warrant compensation expense, respectively. Warrant expense for the periods presented is recorded in research and development as the expense relates to unvested performance based warrants granted to a non-employee.

Commitments

Commitments	3 Months Ended
	Mar. 31, 2016
Commitments And Contingencies Disclosure [Abstract]
Commitments	Note I — Commitments During the three months ended March 31, 2016, the Company entered into leases for approximately $173,000 in laboratory and computer equipment. These leases have 36 month terms, a $1.00 buyout option at the end of the terms and interest rates of 5.0% and 6.01%. The Company accounted for these lease agreements as capital leases.

Other Related Party Transaction

Other Related Party Transactions	3 Months Ended
	Mar. 31, 2016
Related Party Transactions [Abstract]
Other Related Party Transactions	Note J — Other Related Party Transaction During the three months ended March 31, 2016 and 2015, Steven C. Jones, a director of the Company, earned approximately $65,750 and $65,000 respectively, for various consulting work performed in connection with his duties as Executive Vice President of Finance and reimbursement of incurred expenses. Mr. Jones also received $78,900 and $47,500 during the three months ended March 31, 2016 and 2015, respectively as payment of his annual bonus compensation for the previous fiscal years.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	Note I—Subsequent Event On April 20, 2016, the Compensation Committee of the Board of Directors granted 1,525,027 options to certain Executives and key employees of the Company. The options were granted at a price of $7.15 per share and had a weighted average fair market value of $2.50 per option for a total fair market value of $3.8 million. We expect our stock option compensation expense to increase by approximately $1.7 million, $1.4 million, $584,000, and $118,000 in the years ended December 31, 2016, 2017, 2018 and 2019, respectively.

Acquisitions (Tables)

Acquisitions (Tables) - Clarient, Inc. [Member]	3 Months Ended
	Mar. 31, 2016
Summary of Acquisition Date Fair Value of Common Stock Transferred	The acquisition date fair value of common stock transferred is calculated below ($ in thousands, except share and per share amounts): Common Stock Valuation Amount Shares of common stock issued as consideration 15,000,000 Stock price per share on closing date $ 8.04 Value of common stock issued as consideration $ 120,600 Issue discount due to lack of marketability $ (18,090 ) Fair value of common stock at December 30, 2015 $ 102,510
Summary of Estimated Fair Values of Assets Acquired and Liabilities Assumed	The preliminary acquisition fair values below are presented as of December 30, 2015 (in thousands): December 30, 2015 (As Initially Reported) Measurement Period Adjustments December 30, 2015 (As Adjusted) Current assets, including cash and cash equivalents of $890 $ 31,978 $ - $ 31,978 Property and equipment 19,241 - 19,241 Identifiable intangible assets – customer relationships 84,000 - 84,000 Goodwill 143,493 (242 ) 143,251 Total assets acquired 278,712 (242 ) 278,470 Current liabilities (12,631 ) 242 (12,389 ) Deferred tax liability (17,904 ) - (17,904 ) Long-term liabilities (103 ) - (103 ) Net assets acquired $ 248,074 $ - $ 248,074
Schedule of Unaudited Pro Forma Information	The following unaudited pro forma information (in thousands), have been provided for illustrative purposes and are not necessarily indicative of results that would have occurred had the Acquisition been in effect since January 1, 2014, nor are they necessarily indicative of future results. March 31 2015 Revenue $ 54,316 Net (loss) attributable to common stockholders (45,526 ) (Loss) per share $ (0.60 ) Basic 75,277 Diluted 75,277

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Changes in Carrying Amount of Goodwill	The changes in the carrying amount of goodwill for the three month period ended March 31, 2016 and for the year ended December 31, 2015 are as follows (in thousands): March 31, December 31, 2016 2015 Balance as of January 1 $ 146,421 $ 2,929 Goodwill acquired during the period - 143,492 Adjustment to preliminary value of goodwill (Note C) (242 ) - Balance at end of period $ 146,179 $ 146,421
Classes of Intangible Assets	Intangible assets as of March 31, 2016 and December 31, 2015 consisted of the following (in thousands): March 31, 2016 Amortization Period Cost Accumulated Amortization Net Trade Name 24 months $ 3,000 $ 383 $ 2,617 Customer Relationships 156 months 82,930 1,842 81,088 Support Vector Machine (SVM) technology 108 months 500 227 273 Laboratory developed test (LDT) technology 164 months 1,482 443 1,039 Flow Cytometry and Cytogenetics technology 202 months 1,000 243 757 Total $ 88,912 $ 3,138 $ 85,774 December 31, 2015 Amortization Period Cost Accumulated Amortization Net Trade Name 24 months $ 3,000 $ 8 $ 2,992 Customer Relationships 156 months 82,930 247 82,683 Support Vector Machine (SVM) technology 108 months 500 213 287 Laboratory developed test (LDT) technology 164 months 1,482 416 1,066 Flow Cytometry and Cytogenetics technology 202 months 1,000 228 772 Total $ 88,912 $ 1,112 $ 87,800
Estimated Amortization Expense	The estimated amortization expense related to amortizable intangible assets for each of the five succeeding fiscal years and thereafter as of March 31, 2016 is as follows (in thousands): Year Ending December 31, Remainder of 2016 $ 5,246 2017 7,264 2018 5,771 2019 5,771 2020 5,771 2021 5,726 Thereafter 50,225 Total $ 85,774

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Summary of Maturities of Long-term Debt	Maturities of long-term debt at March 31, 2016 are summarized as follows (in thousands): Term Loan Auto Loans Total Long Term Debt Remainder of 2016 $ 413 $ 40 $ 453 2017 550 40 590 2018 550 18 568 2019 550 14 564 2020 52,937 4 52,941 $ 55,000 $ 116 $ 55,116 Less: Current portion of long-term debt (550 ) (46 ) (596 ) Less: Debt issuance costs, net (2,204 ) - (2,204 ) Long-term debt, net $ 52,246 $ 70 $ 52,316

Revenue Recognition and Contr20

Revenue Recognition and Contractual Adjustments (Tables)	3 Months Ended
	Mar. 31, 2016
Revenue Recognition [Abstract]
Adjustment of Transactions Revenue	The table below shows the adjustments made to gross service revenues to arrive at net revenues (in thousands), the amount reported on our statements of operations. Three Months Ended March 31, 2016 2015 Gross service revenues $ 132,720 $ 53,631 Total contractual adjustments and discounts (73,016 ) (30,605 ) Net revenues $ 59,704 $ 23,026

Equity (Tables)

Equity (Tables)	3 Months Ended
	Mar. 31, 2016
Equity [Abstract]
Summary of Stock Option Activity	A summary of the stock option activity under the Company’s plans for the three months ended March 31, 2016 is as follows: Number of Weighted average shares exercise price Options outstanding at December 31, 2015 5,326,505 $ 3.07 Options granted 762,500 6.77 Less: Options exercised 1,218,292 0.92 Options canceled or expired 139,542 4.68 Options outstanding at March 31, 2016 4,731,171 3.42 Exercisable at March 31, 2016 1,753,494 $ 2.32
Summary of Stock-Based Compensation Expense Recognized for Stock Options and Restricted Stock Included in Consolidated Statements of Operations	Stock based compensation expense recognized for stock options and restricted stock and included in the consolidated statements of operations was allocated as follows (in thousands): Three Months Ended March 31, 2016 2015 Research and development expense $ (9 ) $ 55 General and administrative expense 796 287 Total stock based compensation expense $ 787 $ 342
Summary of Warrant Activity	A summary of the warrant activity for the three months ended March 31, 2016 is as follows: Number of Weighted average shares exercise price Warrants outstanding at December 31, 2015 650,000 $ 1.48 Warrants granted — — Less: Warrants exercised — — Warrants canceled or expired — — Warrants outstanding at March 31, 2016 650,000 1.48 Exercisable at March 31, 2016 530,000 $ 1.49

Nature of Business and Basis 22

Nature of Business and Basis of Presentation - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2016Segment
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Number of reportable segments	1

Recently Issued Accounting Gu23

Recently Issued Accounting Guidance - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Accounting Changes And Error Corrections [Abstract]
Current deferred tax assets	$ 16,668	$ 16,668

Acquisitions - Additional Infor

Acquisitions - Additional Information (Detail) - USD ($)	Dec. 30, 2015	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Dec. 28, 2015	Dec. 27, 2015
Business Acquisition [Line Items]
Common stock, shares authorized		250,000,000		250,000,000	250,000,000	100,000,000
Preferred stock, shares authorized					50,000,000	10,000,000
Amortization of intangibles		$ 2,026,000	$ 93,000
Debt issuance costs		$ 2,204,000
GE Medical [Member]
Business Acquisition [Line Items]
Ownership percentage upon conversion of preferred stock		32.00%
Term Loan [Member]
Business Acquisition [Line Items]
Debt issuance costs		$ 2,204,000
Clarient, Inc. [Member]
Business Acquisition [Line Items]
Business acquisition, purchase price in cash payment	$ 73,800,000
Payment for working capital adjustment	$ 6,700,000
Business acquisition, purchase price payment in share	15,000,000
Discount due to lack of marketability of the common stock, percent	15.00%
Fair value of preferred stock consideration	$ 102,510,000
Fair value of preferred stock	$ 8.04
Acquired intangible assets	$ 84,000,000
Amortization of intangibles		$ 1,900,000		$ 36,000
Provisional fair value of accounts receivable acquired	27,600,000
Debt issuance costs				3,300,000
Clarient, Inc. [Member] | General and Administrative Expense [Member]
Business Acquisition [Line Items]
Acquisition related transaction costs				$ 4,700,000
Clarient, Inc. [Member] | Customer Relationships [Member]
Business Acquisition [Line Items]
Acquired intangible assets	$ 81,000,000
Intangible asset amortization period	15 years
Clarient, Inc. [Member] | Trade Names [Member]
Business Acquisition [Line Items]
Acquired intangible assets	$ 3,000,000
Intangible asset amortization period	2 years
Clarient, Inc. [Member] | Revolving Credit Facility [Member]
Business Acquisition [Line Items]
Business acquisition, purchase price in cash payment	$ 9,500,000
Clarient, Inc. [Member] | Term Loan [Member]
Business Acquisition [Line Items]
Business acquisition, purchase price in cash payment	53,600,000
Clarient, Inc. [Member] | Cash on Hand [Member]
Business Acquisition [Line Items]
Business acquisition, purchase price in cash payment	$ 10,700,000
Clarient, Inc. [Member] | Common Stock [Member]
Business Acquisition [Line Items]
Business acquisition, purchase price payment in share	15,000,000
Clarient, Inc. [Member] | Series A Redeemable Convertible Preferred Stock [Member]
Business Acquisition [Line Items]
Business acquisition, purchase price payment in share	14,666,667
Fair value of preferred stock consideration	$ 73,200,000
Fair value of preferred stock	$ 4.99
Carrying amount of preferred stock	$ 28,600,000

Acquisitions - Summary of Acqui

Acquisitions - Summary of Acquisition Date Fair Value of Common Stock Transferred (Detail) - Clarient, Inc. [Member] $ / shares in Units, $ in Thousands	Dec. 30, 2015USD ($)$ / sharesshares
Business Acquisition Equity Interests Issued Or Issuable [Line Items]
Shares of common stock issued as consideration | shares	15,000,000
Stock price per share on closing date | $ / shares	$ 8.04
Value of common stock issued as consideration	$ 120,600
Issue discount due to lack of marketability	(18,090)
Fair value of common stock at December 30, 2015	$ 102,510

Acquisitions - Summary of Estim

Acquisitions - Summary of Estimated Fair Values of Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015	Dec. 30, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Goodwill	$ 146,179	$ 146,421		$ 2,929
Clarient, Inc. [Member]
Business Acquisition [Line Items]
Current assets, including cash and cash equivalents			$ 31,978
Property, plant and equipment			19,241
Identifiable intangible assets – customer relationships			84,000
Goodwill			143,251
Total assets acquired			278,470
Current liabilities			(12,389)
Deferred tax liability			(17,904)
Long-term liabilities			(103)
Net assets acquired			248,074
Clarient, Inc. [Member] | Initially Reported [Member]
Business Acquisition [Line Items]
Current assets, including cash and cash equivalents			31,978
Property, plant and equipment			19,241
Identifiable intangible assets – customer relationships			84,000
Goodwill			143,493
Total assets acquired			278,712
Current liabilities			(12,631)
Deferred tax liability			(17,904)
Long-term liabilities			(103)
Net assets acquired			248,074
Clarient, Inc. [Member] | Measurement Period Adjustments [Member]
Business Acquisition [Line Items]
Goodwill			(242)
Total assets acquired			(242)
Current liabilities			$ 242

Acquisitions - Summary of Est27

Acquisitions - Summary of Estimated Fair Values of Assets Acquired and Liabilities Assumed (Parenthetical ) (Detail) $ in Thousands	Dec. 30, 2015USD ($)
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities [Abstract]
Cash and cash equivalents	$ 890

Acquisitions - Schedule of Unau

Acquisitions - Schedule of Unaudited Pro forma Information (Detail) - Clarient, Inc. [Member] $ / shares in Units, shares in Thousands, $ in Thousands	15 Months Ended
	Mar. 31, 2015USD ($)$ / sharesshares
Business Acquisition [Line Items]
Revenue | $	$ 54,316
Net (loss) attributable to common stockholders | $	$ (45,526)
(Loss) per share | $ / shares	$ (0.60)
Basic | shares	75,277
Diluted | shares	75,277

Goodwill and Intangible Asset29

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill	$ 146,179		$ 146,421	$ 2,929
Amortization of intangibles	$ 2,026	$ 93

Goodwill and Intangible Asset30

Goodwill and Intangible Assets - Changes in Carrying Amount of Goodwill (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Goodwill And Intangible Assets Disclosure [Abstract]
Balance as of January 1	$ 146,421	$ 2,929
Goodwill acquired during the period		143,492
Adjustment to preliminary value of goodwill (Note C)	(242)
Balance at end of period	$ 146,179	$ 146,421

Goodwill and Intangible Asset31

Goodwill and Intangible Assets - Classes of Intangible Assets (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
COST	$ 88,912	$ 88,912
Accumulated Amortization	3,138	1,112
Total	$ 85,774	$ 87,800
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	24 months	24 months
COST	$ 3,000	$ 3,000
Accumulated Amortization	383	8
Total	$ 2,617	$ 2,992
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	156 months	156 months
COST	$ 82,930	$ 82,930
Accumulated Amortization	1,842	247
Total	$ 81,088	$ 82,683
Support Vector Machine (SVM) Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	108 months	108 months
COST	$ 500	$ 500
Accumulated Amortization	227	213
Total	$ 273	$ 287
Laboratory Developed Test (LDT) Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	164 months	164 months
COST	$ 1,482	$ 1,482
Accumulated Amortization	443	416
Total	$ 1,039	$ 1,066
Flow Cytometry and Cytogenetics Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	202 months	202 months
COST	$ 1,000	$ 1,000
Accumulated Amortization	243	228
Total	$ 757	$ 772

Goodwill and Intangible Asset32

Goodwill and Intangible Assets - Estimated Amortization Expense (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Goodwill And Intangible Assets Disclosure [Abstract]
Remainder of 2016	$ 5,246
2,017	7,264
2,018	5,771
2,019	5,771
2,020	5,771
2,021	5,726
Thereafter	50,225
Total	$ 85,774	$ 87,800

Debt - Additional Information (

Debt - Additional Information (Detail)	Dec. 30, 2015USD ($)	Mar. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Line Of Credit Facility [Line Items]
Revolving credit facility, net			$ 8,869,000
Term Loan [Member]
Line Of Credit Facility [Line Items]
Line of credit facility maximum borrowing capacity	$ 55,000,000
Current outstanding borrowings		$ 550,000
Long-term outstanding borrowings		52,200,000
Unamortized transaction costs		$ 2,200,000
Interest rate description		(i) (A) a base rate equal to the greatest of 4%, the prime rate, the federal funds rate plus 0.5% and the one month LIBOR rate plus 1%, plus (B) an initial applicable margin of 6% , or (ii) the (A) LIBOR rate for interest periods from one to twelve months, plus (B) an initial applicable margin of 7%, with a minimum LIBOR of 1.00%. Interest on borrowings under the facility will be reduced to Base Rate plus 5.5% or LIBOR plus 6.50% upon the later of (i) NeoGenomics’ achieving maximum total leverage of less than 2.0 to 1.0 and (ii) January 1, 2017.
Debt instrument covenants description		The Term Loan Facility contains the following financial covenants: (i) maintenance of a maximum total leverage ratio of 4.0 to 1.0 (stepping down over time to 3.25 to 1.0), and (ii) maintenance of a minimum consolidated fixed charge coverage ratio of 1.10 to 1.0 (stepping up over time to 1.25 to 1.0). These covenants are effective beginning with the quarter ending March 31, 2016
Term Loan [Member] | Minimum [Member]
Line Of Credit Facility [Line Items]
Debt instrument covenants fixed charge coverage ratio		1.10%
Debt instrument covenants stepping up over time fixed charge coverage ratio		1.25%
Term Loan [Member] | Maximum [Member]
Line Of Credit Facility [Line Items]
Debt instrument covenants leverage ratio		4.00%
Debt instrument covenants stepping down over time leverage ratio		3.25%
Term Loan [Member] | Scenario One [Member]
Line Of Credit Facility [Line Items]
Debt instrument interest rate applicable margin		6.00%
Term Loan [Member] | Scenario Two [Member]
Line Of Credit Facility [Line Items]
Debt instrument interest rate applicable margin		7.00%
Debt instrument, Leverage ratio		0.020
Term Loan [Member] | Base Rate | Scenario One [Member]
Line Of Credit Facility [Line Items]
Debt instrument variable interest rate		4.00%
Term Loan [Member] | Base Rate | Scenario Two [Member]
Line Of Credit Facility [Line Items]
Debt instrument variable interest rate		5.50%
Term Loan [Member] | Federal Funds Rate Plus [Member] | Scenario One [Member]
Line Of Credit Facility [Line Items]
Debt instrument variable interest rate		0.50%
Term Loan [Member] | LIBOR Rate Plus [Member] | Scenario One [Member]
Line Of Credit Facility [Line Items]
Debt instrument variable interest rate		1.00%
Term Loan [Member] | LIBOR Rate Plus [Member] | Scenario Two [Member]
Line Of Credit Facility [Line Items]
Debt instrument variable interest rate		6.50%
Term Loan [Member] | LIBOR Rate Plus [Member] | Scenario Two [Member] | Minimum [Member]
Line Of Credit Facility [Line Items]
Debt instrument variable interest rate		1.00%
Auto Loan
Line Of Credit Facility [Line Items]
Debt instrument maturity period		5 years
Annual amortization percent in principal amount		1.00%
Debt instrument, Interest rate minimum		0.00%
Debt instrument, Interest rate maximum		5.20%
Auto Loan | Minimum [Member]
Line Of Credit Facility [Line Items]
Debt instrument, Term		36 months
Auto Loan | Maximum [Member]
Line Of Credit Facility [Line Items]
Debt instrument, Term		60 months
Revolving Credit Facility [Member]
Line Of Credit Facility [Line Items]
Line of credit facility maximum borrowing capacity	25,000,000
Debt instrument, Term		5 years
Debt instrument description		(i) (A) a base rate equal to the greatest of the prime rate, the federal funds rate plus 0.5% and the three month LIBOR rate plus 1%, plus (B) an applicable margin ranging from 2.0% to 2.5%, or (ii) the (A) LIBOR rate plus (B) an applicable margin ranging from 3.0% to 3.5%. NeoGenomics will also pay 0.25% per year on any unused portion of the revolver.
Debt instrument covenants description		The Revolving Credit Facility contains the following financial covenants: (i) maintenance of a maximum total leverage ratio (funded indebtedness (including the outstanding amounts under the Credit Facilities), plus capitalized lease obligations, divided by EBITDA) of not more than 4.0 to 1.0 (stepping down over time to 3.25 to 1.0), (ii) maintenance of a minimum consolidated fixed charge coverage ratio (EBITDA less capital expenditures not financed with debt or certain equity), divided by the sum of cash interest expense, scheduled payments and mandatory prepayments of principal on indebtedness, taxes and restricted payments) of at least 1.1 to 1.0 (stepping up over time to 1.25 to 1.0) and (iii) maintenance of a minimum cash velocity equal to or greater than 80%. These covenants are effective beginning with the quarter ending March 31, 2016. The Company was in compliance with such all covenants as of March 31, 2016.
Debt instrument covenants minimum cash velocity percentage		80.00%
Debt instrument, maturity date		Dec. 30, 2020
Available credit		$ 25,000,000
Revolving Credit Facility [Member] | Other Current Assets [Member]
Line Of Credit Facility [Line Items]
Unamortized transaction costs		$ 1,200,000
Revolving Credit Facility [Member] | Minimum [Member]
Line Of Credit Facility [Line Items]
Debt instrument covenants fixed charge coverage ratio		1.10%
Debt instrument covenants stepping up over time fixed charge coverage ratio		1.25%
Revolving Credit Facility [Member] | Maximum [Member]
Line Of Credit Facility [Line Items]
Debt instrument covenants leverage ratio		4.00%
Debt instrument covenants stepping down over time leverage ratio		3.25%
Revolving Credit Facility [Member] | Scenario One [Member] | Minimum [Member]
Line Of Credit Facility [Line Items]
Debt instrument interest rate applicable margin		2.00%
Revolving Credit Facility [Member] | Scenario One [Member] | Maximum [Member]
Line Of Credit Facility [Line Items]
Debt instrument interest rate applicable margin		2.50%
Revolving Credit Facility [Member] | Scenario Two [Member]
Line Of Credit Facility [Line Items]
Fee percentage on unused portion		0.25%
Revolving Credit Facility [Member] | Federal Funds Rate Plus [Member] | Scenario One [Member]
Line Of Credit Facility [Line Items]
Debt instrument variable interest rate		0.50%
Revolving Credit Facility [Member] | LIBOR Rate Plus [Member] | Scenario One [Member]
Line Of Credit Facility [Line Items]
Debt instrument variable interest rate		1.00%
Revolving Credit Facility [Member] | LIBOR Rate Plus [Member] | Scenario Two [Member] | Minimum [Member]
Line Of Credit Facility [Line Items]
Debt instrument variable interest rate		3.00%
Revolving Credit Facility [Member] | LIBOR Rate Plus [Member] | Scenario Two [Member] | Maximum [Member]
Line Of Credit Facility [Line Items]
Debt instrument variable interest rate		3.50%
Letter of Credit Sub Facility [Member]
Line Of Credit Facility [Line Items]
Line of credit facility maximum borrowing capacity	$ 1,000,000
Revolving Credit Facility and Letter of Credit Sub Facility [Member]
Line Of Credit Facility [Line Items]
Percentage of borrowing base	0.85
Revolving credit facility, net		$ 0

Debt - Schedule of Maturities o

Debt - Schedule of Maturities of Long Term Debt (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Line Of Credit Facility [Line Items]
Remainder of 2016	$ 453
2,017	590
2,018	568
2,019	564
2,020	52,941
Long-term Debt	55,116
Less: Current portion of long-term debt	(596)	$ (600)
Less: Debt issuance costs, net	(2,204)
Long-term portion of loans, net	52,316	$ 52,336
Term Loan [Member]
Line Of Credit Facility [Line Items]
Remainder of 2016	413
2,017	550
2,018	550
2,019	550
2,020	52,937
Long-term Debt	55,000
Less: Current portion of long-term debt	(550)
Less: Debt issuance costs, net	(2,204)
Long-term portion of loans, net	52,246
Auto Loan
Line Of Credit Facility [Line Items]
Remainder of 2016	40
2,017	40
2,018	18
2,019	14
2,020	4
Long-term Debt	116
Less: Current portion of long-term debt	$ (46)

Class A Redeemable Convertibl35

Class A Redeemable Convertible Preferred Stock - Additional Information (Detail) - Series A Redeemable Convertible Preferred Stock [Member] - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015	Dec. 30, 2015
Temporary Equity [Line Items]
Temporary equity, shares issued	14,666,667	14,666,667	14,666,667
Temporary equity, face value	$ 0.01	$ 0.01	$ 7.50
Temporary equity, liquidation value			$ 110
Temporary equity, fair value			$ 73.2
Temporary equity issued, price per share			$ 4.99
Temporary equity issue discount			$ 36.8
Temporary equity value of beneficial conversion feature	$ 44.7
Temporary equity recognized amount of beneficial conversion feature	$ 1.8

Revenue Recognition and Contr36

Revenue Recognition and Contractual Adjustments - Adjustment of Transactions Revenue (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenue Recognition [Abstract]
Gross service revenues	$ 132,720	$ 53,631
Total contractual adjustments and discounts	(73,016)	(30,605)
Total Revenue, net	$ 59,704	$ 23,026

Equity - Summary of Stock Optio

Equity - Summary of Stock Option Activity (Detail)	3 Months Ended
	Mar. 31, 2016$ / sharesshares
Equity [Abstract]
Stock options, beginning balance | shares	5,326,505
Stock options, granted | shares	762,500
Stock options, exercised | shares	1,218,292
Stock options, canceled or expired | shares	139,542
Stock options, ending balance | shares	4,731,171
Stock options, exercisable, ending balance | shares	1,753,494
Weighted average exercise price, beginning balance | $ / shares	$ 3.07
Weighted average exercise price, granted | $ / shares	6.77
Weighted average exercise price, exercised | $ / shares	0.92
Weighted average exercise price, canceled or expired | $ / shares	4.68
Weighted average exercise price, ending balance | $ / shares	3.42
Weighted average exercise price, exercisable, ending balance | $ / shares	$ 2.32

Equity - Additional Information

Equity - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation cost	$ 4,000,000
Unrecognized share-based compensation expense, weighted-average recognition period	1 year 4 months 24 days
Stock compensation expense	$ 787,000	$ 342,000
Research And Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense	(9,000)	55,000
Research And Development Expense [Member] | Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense	$ (84,000)	$ 59,000

Equity - Summary of Stock-Based

Equity - Summary of Stock-Based Compensation Expense Recognized for Stock Options and Restricted Stock Included in Consolidated Statements of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 787	$ 342
Research And Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	(9)	55
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 796	$ 287

Equity - Summary of Warrant Act

Equity - Summary of Warrant Activity (Detail) - Warrant [Member]	3 Months Ended
	Mar. 31, 2016$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants outstanding, beginning balance | shares	650,000
Warrants, granted | shares	0
Warrants, exercised | shares	0
Warrants, canceled or expired | shares	0
Warrants outstanding, ending balance | shares	650,000
Warrants exercisable, ending balance | shares	530,000
Weighted average exercise price, warrants outstanding, beginning balance | $ / shares	$ 1.48
Weighted average exercise price, warrants granted | $ / shares	0
Weighted average exercise price, warrants exercised | $ / shares	0
Weighted average exercise price, warrants canceled or expired | $ / shares	0
Weighted average exercise price, warrants outstanding, ending balance | $ / shares	1.48
Weighted average exercise price, warrants exercisable, ending balance | $ / shares	$ 1.49

Commitments - Additional Inform

Commitments - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Contractual Obligation [Line Items]
Agreement for purchase of equipment	$ 173,000	$ 2,525,000
Laboratory and Computer Equipment [Member]
Contractual Obligation [Line Items]
Agreement for purchase of equipment	$ 173,000
Interest rate	5.00%
Laboratory and Computer Equipment [Member] | 36 Month Term [Member]
Contractual Obligation [Line Items]
Lease term period	36 months
Buyout option	$ 1
Interest rate	6.01%

Other Related Party Transacti42

Other Related Party Transactions - Additional Information (Detail) - Executive Vice President [Member] - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Related Party Transaction [Line Items]
Fees for consulting work performed	$ 65,750	$ 65,000
Payment of annual bonus compensation	$ 78,900	$ 47,500

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - USD ($)	Apr. 20, 2016	Mar. 31, 2016	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Subsequent Event [Line Items]
Options, grant date price		$ 6.77
Scenario, Forecast | 2016 [Member]
Subsequent Event [Line Items]
Expected stock option compensation expense increase						$ 1,700,000
Scenario, Forecast | 2017 [Member]
Subsequent Event [Line Items]
Expected stock option compensation expense increase					$ 1,400,000
Scenario, Forecast | 2018 [Member]
Subsequent Event [Line Items]
Expected stock option compensation expense increase				$ 584,000
Scenario, Forecast | 2019 [Member]
Subsequent Event [Line Items]
Expected stock option compensation expense increase			$ 118,000
Subsequent Event [Member] | Certain Executives and Key Employees [Member]
Subsequent Event [Line Items]
Options, number granted	1,525,027
Options, grant date price	$ 7.15
Options, weighted average fair market value	$ 2.50
Options granted, fair market value	$ 3,800,000